Research programme: ovarian reserve modulation - PregLem

Drug Profile

Research programme: ovarian reserve modulation - PregLem

Alternative Names: PGL-1001; PGL1

Latest Information Update: 22 Mar 2011

Price : $50

At a glance

  • Originator Ipsen
  • Developer PregLem
  • Class
  • Mechanism of Action Follicle stimulating hormone modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Female infertility

Most Recent Events

  • 22 Mar 2011 Preclinical development is ongoing in Switzerland
  • 07 Oct 2010 PregLem has been acquired by Gedeon Richter
  • 27 Jun 2007 Preclinical trials in Female infertility in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top